| Logo | Name | Σ | Employees | ||
|---|---|---|---|---|---|
 |  BIOTECanada Solving for today. Building for tomorrow. BIOTECanada is the national industry association voice. With over 230 member companies, the Association’s membership is representative of the broader Canadian biotech ecosystem which is national in scope and comprised of pre-commercial biotech companies, global pharma and biotech companies, investors, incubator and accelerator organizations, and academia. In the context of global population growth and corresponding climate change, food sustainability, and human health needs, the biotechnology industry plays a vital role in developing solutions to help address the resulting human health and environmental challenges. Type: | 6 | 1 | 5 | 26 |
 | MedTech in France [Automatic translation follows] We are the French medical technology companies, we innovate every day for patients! Created in 2013, MedTech in France currently brings together more than 40 French companies in the MedTech sector from e-health and telemedicine to optical technologies, surgical robotics, and medical imaging. The Association develops concrete solutions to promote market access, innovations, and showcase French excellence in medical technologies. It has also set itself the mission of developing French champions internationally. MedTech in France has set itself a triple ambition: > provide medical solutions for patients and healthcare workers > provide economic and organizational benefits for … Type: | 26 | 5 | 23 | 7 |
 | Kickston [Automatic translation follows] Fundraising I M&A Kickston is an investment bank that supports entrepreneurs in their fundraising and M&A operations. Industries: Consumer & Tech B2B • Fundraising: €2 to €10M • Sale: Operations up to €15M Are you interested in our approach? Contact us! contact@kickston.co Type: | 32 | 1 | 32 | 8 |
 | Algorithmiq We develop advanced quantum algorithms to solve complex problems in life sciences Algorithmiq is a company developing advanced algorithms to solve complex problems in life sciences. Our mission is to revolutionise life sciences by exploiting the potential of quantum computing to solve currently inaccessible problems. We combine our expertise in quantum information, complex systems, and computational physics to develop algorithms that run on near-term quantum devices to discover new drugs and develop new materials Quantum physics, Complex networks, Quantum computing, Quantum simulations, Quantum chemistry, Quantum software, and Computational physics Type: | 12 | 0 | 12 | 40 |
 | LifeArc Transforming promising life science ideas into medical breakthroughs that change patients’ lives. LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives. We are self-funding and specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. This includes Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) … Type: | 18 | 3 | 13 | 389 |
 | Citeline Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. Type: | 13 | 10 | 3 | 392 |
 | OBN (UK) Ltd The membership organisation supporting & bringing together UK’s life sciences companies, corporate partners & investors OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors. Our c.500 member companies are located across the Golden Triangle and beyond, and benefit from our networking, partnering, purchasing, advising, and advocacy activities. OBN organises BioTrinity - Europe's Leading Investment and Biopartnering Conference, find out more at www.biotrinity.com. Networking Events, Partnering (BioTrinity), Advising: Cluster Analysis and Business Development, Group Purchasing Consortium, Advocacy, Conferences, BioTech, and Life Sciences Type: | 9 | 4 | 5 | 30 |
 | ELICIT PLANT The only efficient Bio-Intrant to fight Water Stress ELICIT PLANT is an AGtech company and a pioneer in the stimulation of field-grown plants through the use of phytosterols. By reducing plant water stress, our patented technology increases yield in situation of lack of water. Elicit Plant develops and provides new effective prevention products against the stress suffered by plants grown by the intake of exogenous phytosterols in the field. Elicit Plant offers a novel solution for reducing water consumption for the cultivation of targeted plants and helps to fight against water stress. Elicit Plants develops a methodology to collect soil, … Tags: FrenchTech2030 Type: | 18 | 10 | 11 | 75 |
 | Neoplants The first generation of plants bioengineered to fight air pollution. www.neoplants.com The first plant-microbiome systems bioengineered to purify indoor air. | 15 | 10 | 8 | 34 |
 |  Amolyt Pharma Advancing peptides for the treatment of rare endocrine and related diseases Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, … Tags: FrenchTech2030 Type: | 11 | 10 | 1 | 54 |
 | Merieux Equity Partners Invested Investors Merieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and Growth/Buyout. As an independent General Partner - registered under the French Financial Markets Authority AMF ("Autorité des Marchés Financiers") - Merieux Equity Partners currently manages 5 main funds, representing more than €1 billion of Commitments, and has supported over 45 companies in Europe and North America since its creation - in Venture Capital and Growth/Buyout. Our passion is to work alongside entrepreneurs and companies with an ambitious growth plan, offering them privileged access to our sector-expertise and … Type: | 10 | 8 | 5 | 37 |
 | DNA Script Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine. Synthetic Biology, Biotechnology, DNA synthesis, Sciences, Research, Development, Start-up, and Technology Tags: FrenchTech120 FrenchTech2030 Type: | 36 | 13 | 25 | 186 |
 | Eli Lilly and Company We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center … Type: | 60 | 16 | 33 | 44,396 |
 | Eight Roads We back and partner with game-changing technology and healthcare companies in China, Europe, India, Japan and the US. Eight Roads Ventures is a global venture capital firm backed by Fidelity that helps entrepreneurs scale. We back and partner with game-changing technology and healthcare companies. With a presence in China, Europe, India and Japan, our global platform has 50+ years of venture investing experience, $11 Bn in AUM, over 300 portfolio companies and 60+ IPOs. Healthcare, Biosciences & Life Sciences, Consumer Technology, Internet & e-Commerce, FinTech & FinServ, Telecommunications, Food & Agriculture, Education and Skills Development, Enterprise Tech, Pharmaceuticals, Edu Tech, … Type: | 35 | 9 | 19 | 215 |
 | Casdin Capital, LLC Life Science Investments Casdin Capital, LLC is a New York-based research investment firm focused on the innovations in molecular medicine currently reshaping Life Sciences and healthcare. Founded in 2011, and with an eye to long-term returns and disruptive technologies, Casdin Capital is an expert working with experts, benefiting from its position at the crossroads of the science and investment communities. As trusted investor-partners in both private and public companies, we collaborate with industry leaders to fuel their visions, adding energy, insight, and experience to our over $2.4 billion under management. As we push into new markets and new developments, we … Type: | 6 | 2 | 0 | 53 |
 | Andreessen Horowitz Software is eating the world Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, fintech and games spaces. a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, … Type: | 73 | 29 | 20 | 724 |
 | 4BIO Capital London-based venture fund investing in advanced therapies 4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious … Type: | 7 | 2 | 5 | 17 |
 | Institut de la Vision [Automatic translation follows] From the movement of knowledge to the therapeutic approaches of tomorrow Built in the heart of the Hôpital national des 15-20, the Vision Institute is one of the largest integrated research centers on vision diseases in Europe. Designed as a place of gathering and exchange, it brings together on the same site fundamental, clinical and industrial research, thus promoting the sharing of concepts and techniques, the meeting of complementary skills and expertise and the emergence of new avenues of research. Researchers, doctors and manufacturers work together to discover and validate new therapies, preventive solutions, as well as … Type: | 22 | 7 | 10 | 226 |
 | Crédit Mutuel Innovation [Automatic translation follows] Our relationships bring value Crédit Mutuel Innovation is the subsidiary specializing in venture capital investments of Crédit Mutuel Equity (€4 billion in capital under management). It invests in equity tickets ranging from €1 to €20 million in innovative companies in deeptech, digital and life sciences. Crédit Mutuel Innovation allows entrepreneurs to develop their growth potential by connecting them to companies in its ecosystems. Because it takes more than 5 years to create a world leader, Crédit Mutuel Innovation invests its own capital sustainably and builds long-term relationships with the entrepreneurs it supports. Type: | 55 | 23 | 41 | 18 |
 | UI Investissement [Automatic translation follows] Together, investing for a better future A specialist in the development of unlisted French companies, UI has been committed and invested for over 50 years alongside managers of startups, SMEs and growing mid-cap companies to help economically and sustainably successful companies emerge and develop. UI Investissement manages around €1.5 billion in assets and invests with 300 managers in sectors that are essential to society, such as health, agribusiness, industry and services. Development and transmission capital, the historical core of UI's activity, represents over half of the assets under management and allows over 50 companies to benefit from … Type: | 107 | 47 | 46 | 111 |
 | BIOTECHFINANCES [Automatic translation follows] 1st weekly newsletter of specialized information, biotech, medtech, e-health, finance published by Jacques Bernard Taste PRESENTATION The weekly letter Biotech Finances approaches from an economic and financial angle all the questions related to the development of the biotechnology sector and more broadly of life sciences. Our target readership is mainly composed of biotechnology companies oriented towards health and the development of new therapies and new treatments for diseases, pharmaceutical companies (big pharma and other laboratories), investors, business angels, investment funds, venture capital, specialized in the biotech sector, institutions, legal advisors, development experts, and service providers and equipment … Type: | 17 | 5 | 3 | 9 |
 |  MaaT Pharma The leading microbiome company in oncology MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process … Type: | 29 | 10 | 23 | 84 |
 | Sensorion Our mission: find solutions for hearing disorders Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs … Type: | 14 | 8 | 6 | 75 |
 | Cure51 We want every patient to become a Cancer Survivor. The first worldwide clinical and molecular database of exceptional survivors leading the path to new therapies against cancer. Type: | 5 | 3 | 2 | 25 |
 | BT Group We’re one of the world’s leading communications services companies. At BT Group, the solutions we sell are integral to modern life. Our purpose is as simple as it is ambitious: we connect for good. There are no limits to what people can do when they connect. And as technology changes our world, connections are becoming even more important to everyday life. Today, that’s truer than ever. The connections we make are helping solve the world’s biggest challenges such as the global pandemic, climate change and cyber security. Through the power of technology, we’re supporting customers to live, work and play … Type: | 15 | 11 | 2 | 77,849 |
 | Bruntwood 💡 Creating Thriving Cities: Workspace | Laboratories | Retail | Leisure Workspace | Laboratories | Retail | Leisure We own, let and manage outstanding buildings, workspace, innovation and science facilities. Our purpose: creating thriving cities. This purpose fuels our passion for supporting arts and culture, our deep community engagement and our ambitious plans for future growth. It ensures every investment and decision we make benefits our customers, our communities and our colleagues: because when our cities thrive, so do we. Our commitment to creating thriving cities has helped us to grow into a company with more than £1bn in assets … | 20 | 1 | 14 | 677 |
 | World Bio Markets & Bio Innovations Midwest Driving the commercialisation of the Bioeconomy We connect markets and create relationships to drive the commercialisation of the bioeconomy. For years World Bio Markets (est. 2005) and World Bio Market Insights (est. 2015) have delivered market leading events and content for our clients and readers around the world. Now in 2024, we are delighted to be taking our event to the U.S. with Bio Innovations Midwest. Bio Innovations Midwest – 24-25 September 2024, Omaha: https://bioinnovationsmidwest.com/ World Bio Markets – 25-26 June 2025, The Hague: https://www.worldbiomarkets.com/ World Bio Market Insights – News & inspiration for the bioeconomy: https://worldbiomarketinsights.com/ We are committed … Type: | 30 | 2 | 27 | 16 |
 | ARCH Venture Partners We are contrarian. We are bold. We are imaginative risk takers. Early stage venture firm focused on life science discoveries to prevent, detect and cure disease. Type: | 2 | 2 | 0 | 57 |
 | McDermott Will & Emery A global law firm helping propel today’s most respected, dynamic and important organizations. McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20+ locations globally, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve. Attorney Advertising. Prior results do not guarantee a similar outcome. Type: | 11 | 4 | 6 | 3,142 |
 | Dechert LLP Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors. © 2024 Dechert LLP. All rights reserved. This information should not be considered as legal opinions on specific facts or as … Type: | 10 | 6 | 5 | 2,185 |
 | SV Health Investors Investing in tomorrow's healthcare breakthroughs SV Health Investors is a specialist healthcare fund manager, investing across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology. Alongside our core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia. Venture Capital, Biotechnology, Medical Devices, Healthcare services, Private Equity, and Dementia Type: | 10 | 1 | 10 | 100 |
 | RELEVATION The Global digital fundraising Summit for PropTech startups Relevation.org is the global digital investment summit in UrbanTech; a 2 days event of match-making between investors (BA, family offices, VC, CVC...) and startups across all the stages of maturity in fund raising process Type: | 24 | 3 | 23 | 2 |
 | ICREA - Institució Catalana de Recerca i Estudis Avançats The need to know ICREA, Catalan Institution for Research and Advanced Studies, is a foundation supported by the Catalan Government and guided by a Board of Trustees. ICREA was created in response to the need to seek new hiring formulas that would make it possible to compete with other research systems on a similar footing by focusing on hiring only the most talented and extraordinary scientists and academics. ICREA is an institution without walls. It works hand in hand with Catalan universities and research centres to integrate ICREA research professors in the Catalan research system. ICREA offers permanent, tenured positions … Type: | 1 | 1 | 0 | 60 |
 | Institut G9+ L'Interclubs Numérique des Alumni des Grandes Écoles & Universités The G9 + Institute is a plural and apolitical think tank, promoting digital development in France. Federating 24 graduate communities of universities and colleges, and 50000 alumni, the G9 + Institute is one of the reference think tanks of digital for more than 22 years. Engaged in its historical mission of consultative source of proposals, the G9 + Institute wants to allow its members and friends to confront their ideas, deepen them and make them known. It brings an investigative, constructive and audacious light by publishing white papers and organizing about … Type: | 45 | 12 | 32 | 11 |
 | Frst We are the first believers The world produces a handful of legendary entrepreneurs a year. We are entrepreneurs too, and have designed from scratch the ideal partner for these unique people. A meaningful check at Day One, often even before the company actually exists. A responsive, reliable and knowledgeable counterpart with aligned interests. A long-term relationship we hope will last a decade. We are Frst. -- €200m+ AUMA invested at day one in 50+ companies to date. Full portfolio on frst.vc Type: | 7 | 6 | 0 | 6 |
 | Shockwave Medical Making waves for underserved patients with cardiovascular disease via novel technologies. ⚡🌊 Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotripsy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. Stay connected with … Type: | 2 | 2 | 1 | 1,263 |
 | GV (Google Ventures) Launched as Google Ventures in 2009, GV supports innovative founders moving the world forward. GV supports innovative founders moving the world forward. We invest across the life sciences, consumer, enterprise, crypto, climate, and frontier technology sectors. With Alphabet as a sole limited partner, GV operates on long time horizons and deals in decades, not rounds. Our operating partners help startups at the earliest stages of company-building across design, equity, diversity & inclusion, talent, and engineering. We also help startups interface with Google, providing unique access to the world’s best technology and talent. Launched as Google Ventures in 2009, GV has … Type: | 15 | 5 | 8 | 298 |
 | HCVC We help fearless founders tackle hard problems with capital, resources and collaboration. HCVC is a venture capital firm that helps fearless founders tackle hard problems with capital, resources and collaboration. deeptech, venture capital, Seed, hardtech, pre-seed, and series A Type: | 47 | 9 | 32 | 24 |
 | Supernova Invest European deeptech VC, focused on high-growing start-ups and cutting-edge technologies Supernova Invest is a European multi-stage VC firm with currently €800m AUM. Our team provides unparalleled expertise and patient capital in the fields of Digital, Industrial Technologies, Healthcare and Cleantech to support high-growth, deeptech start-ups and scale them globally. We support disruptive tech companies such as Soitec, Ynsect, Alice & Bob, Gleamer, Prophesee, Crowdsec, UnitySC or Unseenlabs. The Supernova team exited +25 companies through top IPO and M&A deals. The team is composed of +20 experienced investors with a unique ability to understand both the underlying technologies and the most … Type: | 61 | 19 | 44 | 35 |
 | Kima Ventures We fund ambitious, cohesive teams with stellar learning and execution curves. Investing in 2 to 3 startups per week, all over the world. Type: | 48 | 38 | 1 | 20 |
 | Chausson Partners We match smart money with great companies Chausson Finance is a leading fundraising advisory firm, providing deal making and equity story advice, as well as devoted support to inspiring founders. We helped shape +250 deals, and raise $1Bn. Our community of clients include leadership teams funded by Accel, Balderton, Alven and other top venture investors. Fundraising, Corporate Finance, Venture Capital, investment banking, equity rounds, M&A, Series A, Series B, and Equity Financing Type: | 18 | 2 | 16 | 16 |
 | KREAXI Financing partner for innovative start-ups KREAXI is one of the top French leaders in seed and venture capital, with €150m under management, 550 companies invested since last 30 years (of which 27 went public), 60 active portfolio companies, with a team of 16 persons based in Lyon and Paris. Type: | 40 | 18 | 23 | 10 |
 | Voisin Consulting Life Sciences (VCLS) Global reference partner to expedite access of HealthTech products to regulated markets. From discovery to product launch and lifecycle management At VCLS (Voisin Consulting Life Sciences), regulatory science guides Biotechnology, Pharmaceutical and Medtech manufacturers throughout product development and commercialization. Starting early in the process, from discovery to the patient, VCLS assists innovators in designing optimized product development plans and regulatory strategies, combining the health ecosystem with commercial success. With a presence in seven locations across three continents and over 200 employees, VCLS serves a broad range of healthtech developers and their investors. Together, we accompany global stakeholders to expedite HealthTech … Type: | 8 | 1 | 6 | 221 |
 | L'AGEFI [Automatic translation follows] The leading information service for finance professionals in France. AGEFI is the leading information service for finance professionals in France. AGEFI relies on the 1st financial editorial team composed of 50 expert journalists in finance, allowing it to cover all sectors of finance: Asset Management, Private Equity, Institutional Investors, Cash & Risk, Heritage. Every day, our journalists analyze, decipher and delve deeper into the news and offer our readers unique information with very high added value (alerts, articles, analyses, in-depth reports, etc.) essential to their activity. AGEFI, as the facilitator of the communities that make up finance, … Type: | 178 | 91 | 115 | 172 |
 | Protera Smarter proteins for a sustainable future. By 2050, the world's population will surpass 10 billion people. To feed the current population and future generations we need to address global food challenges, today. How can we solve this problem without overwhelming the planet? And how can we deliver higher quality, more nutritious food for everyone? With Protera’s Natural IntelligenceTM technology, we believe the future is already here. Protera’s technology uses predictive algorithms that calculate millions of amino acid combinations and simulate protein patterns in a matter of seconds. Our technology is based in Deep Learning and allows us to shine a … Type: | 3 | 0 | 3 | 32 |
 | RE:CHEMISTRY - By GFBio We make everyday products safe and sustainable. We aim to end chemical pollution in consumer products. We make everyday products safe and sustainable. We aim to end chemical pollution in consumer products by replacing harmful petro-based ingredients. Biochemicals, Levulinic Acid, Application Development, R&D, Green Chemistry, and Formulation Development Type: | 5 | 2 | 3 | 36 |
 | Cambridge Innovation Capital A leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies. Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. CIC currently manages over £500 million and has invested in 30+ companies. We invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics. IP Commercialisation, Venture Capital, healthcare, … Type: | 17 | 6 | 6 | 33 |
 | La villa numeris [Automatic translation follows] Think digital, make real La villa numeris is an independent think tank that promotes a European model of digital based on humans. Our mission: to enable decision-makers to understand and anticipate societal and economic transformations, to act accordingly, to raise awareness and mobilize to give meaning to organizations and succeed in their transformation. La villa numeris is an association under the 1901 Law financed by its members and by the sale of services. New Culture of Work, Working Differently, Connected Territories, Fake news, Digital citizen, Blockchain, AI, and Citizenship Type: | 38 | 4 | 23 | 10 |
 | Ecofi [Automatic translation follows] Assets for the future Management that influences tomorrow In 1972, our first Sicav was born, which has since become Epargne Ethique Flexible. 1st sharing fund in Europe created in 1983, launch of our solidarity fund in 2002, range of 100% SRI* funds in 2019, first French management company to adopt the status of mission-driven company in 2020... Ecofi works every day to combine financial performance and respect for Man and the Planet. This commitment has only grown over the years. Today, Ecofi is more than ever taking a long-term approach, combining control, involvement and sincerity to build, … Type: | 39 | 8 | 22 | 97 |
 | May Health We are bringing a modern approach to the treatment of PCOS with our investigational Ovarian Rebalancing Treatment. May Health, formerly AblaCare, is developing a modern approach to PCOS. Type: | 3 | 2 | 2 | 23 |
 | Bioptimus We build foundation models that will transform biology. We use cutting-edge technology to transform multiscale data into actionable representations to fuel breakthrough discoveries. Join us on our mission to build foundation models that transform biology. artificial intelligence, biology, and foundation models Type: | 5 | 3 | 4 | 18 |
 | CONCILIO Your key to better care. CONCILIO is revolutionizing healthcare access with its unique MEDICAL CONCIERGE service, which combines cutting-edge technology with a team fully dedicated to the well-being of employees and their families. We support businesses and their employees daily through a wide range of services: doctor recommendations, easy appointment scheduling, teleconsultations, digital health assessments, and preventive programs. Concilio also offers its partners the chance to benefit from its advanced technological expertise through CONCILIO SOLUTIONS. This service enables professionals to innovate, increase profitability, and leverage our proven technologies, teams, and processes. E-santé, Téléconsultation, Recherche de Médecins, Bilan Santé, téléconseil médical, … Type: | 20 | 5 | 13 | 43 |
 | Headline We help founders win, bigger Headline is a Venture Capital firm actively on the ground in 7 cities around the world. We invest across geographies, leading rounds at every stage. Once we commit to a team, we go to the ends of the earth to make their success global. Our Early Stage Funds are based in the US, Europe, Asia, and Brazil, and invest locally. Our San Francisco-based Growth Fund invests globally from Series B and beyond, working in collaboration with our Early Stage Teams. The sizes and locations of these funds make it possible for us to see local … Type: | 20 | 12 | 8 | 207 |
 | Cathay Capital Cathay Capital, Connecting People to Achieve the Extraodinary About Cathay Capital Group Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now … Type: | 46 | 9 | 34 | 148 |
 | Tenpoint Therapeutics Ltd Vision-restoring engineered cell-based therapeutics & in vivo reprogramming. Tenpoint Therapeutics is a vision-restoring engineered cell-based therapeutics company. We are embracing a new opportunity to fundamentally reshape the future for people with ocular diseases. We have an ambitious goal with global impact. Type: | 2 | 2 | 0 | 27 |
 | EKTAH [Automatic translation follows] New nutritional solutions to reduce human and animal body weight gain EKTAH's mission is to restore pleasure to each individual in a situation of obesity or overweight, allowing them to reduce their body weight and return to a healthy, tasty and balanced diet without depriving themselves. The company's scientific approach consists of identifying lipid "decoys (or agonists)" capable of activating oro-gustatory receptors more intensely than dietary fatty acids, thus allowing the brain to trigger early satiety, which will immediately lead to a reduction in food intake. These decoys do not provide calories and would also trigger a … | 19 | 7 | 17 | 2 |
 | ENYO Pharma Developing therapeutics for diseases with impaired kidney function ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor. Type: | 8 | 3 | 5 | 32 |
 | RebrAIn ReBrain standardizes targeting for DBS and brain lesion surgeries in Parkinson and essential tremor diseases RebrAIn offers a precise targeting technology for Deep Brain Stimulation (DBS). This is achieved through an algorithm based on Artificial Intelligence and a collaborative health data registry. With this innovative technology, developed to effectively identify the areas of the brain to be treated, ReBrain simplifies and standardizes DBS by reducing the risks and making it less traumatic, thus allowing more patients worldwide to be treated. Type: | 14 | 7 | 6 | 15 |
 | Catsalyze We improve your enzymes. Catsalyze will revolutionize enzymatic biocatalyze. Our proprietary technology allows us to graft enzymes around a protein ring, which gives them strong advantages such as increased stability, solubility, efficiency but also the possibility of assembling these grafted rings to create perfectly colocalized enzymatic cascades. . So extremely effective. Our challenge? Transform biomass in a gentle and clean way and through accelullar enzymatic catalysis into chemical bricks classically petrosourced and synthesized with pollution. The future of chemistry passes through Catsalyze. Type: | 27 | 5 | 23 | 2 |
 | GOURMEY 🌎 We create sustainable cultivated meat delights for an uncompromising and conscious generation. [join.gourmey.com] GOURMEY is France's pioneering cultivated meat company. 🌎 We create sustainable cultivated meat delights for an uncompromising and conscious generation. > Join.gourmey.com Type: | 34 | 10 | 28 | 103 |
 | datacraft [Automatic translation follows] The data scientists Club datacraft allows an exchange of best practices between data experts. It is a unique Club model, inspired by mentoring, and designed to allow data scientists/data engineers to train among peers and allow companies to accelerate their AI/data projects Access to the Club is through an annual membership. Type: | 53 | 8 | 40 | 16 |
 | Gradient Denervation Technologies Transforming the treatment of pulmonary hypertension A solution for patients suffering from heart failure with pulmonary hypertension. Type: | 1 | 1 | 0 | 14 |
 | Moon Surgical Empowering the Surgeon Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics. medical device, minimally invasive surgery, digital surgery, comanipulation, AI, Machine Learning, Surgery, Laparoscopy, and Surgical Robotics Tags: FrenchTech120 FrenchTech2030 Type: | 15 | 8 | 8 | 74 |
 | IXO PRIVATE EQUITY [Automatic translation follows] iXO Private Equity. Invest, Invest, Succeed, Together iXO Private Equity is a management company that mainly carries out LBO and development capital transactions. Its team is made up of 19 people, including 14 professional investors with complementary experience. iXO Private Equity is one of the largest independent French players in small and mid-cap. The management company, based in Toulouse, now manages more than €610 million in assets and invests per project from €2 to €15 million in equity, primarily in companies in the greater South of France and Rhône-Alpes. Type: | 37 | 11 | 30 | 31 |
 | Meridiam For people and the planet - delivering transformational infrastructure, for the long term. Meridiam was founded in 2005 by Thierry Déau, with the belief that the alignment of interests between the public and private sector can provide critical solutions to the collective needs of communities. Meridiam is an independent investment Benefit Corporation and an asset manager. The firm specializes in the development, financing, and long-term management of sustainable public infrastructure in three core sectors: sustainable mobility, critical public services and innovative low carbon solutions. With offices in Addis Ababa, Amman, Dakar, Istanbul, Luxembourg, Paris, Vienna, Libreville, Johannesburg and Washington, Meridiam … Type: | 71 | 21 | 48 | 377 |
 | Andera Partners The Power of And Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra). Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our … Type: | 35 | 20 | 19 | 128 |
 | Asceneuron SA Targeting the root cause of neurodegeneration Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & … Type: | 3 | 2 | 2 | 20 |
 | Turbine We are building the world’s leading predictive simulation of patient biology. Truly meaningful medicine comes from breakthroughs?in deeply understanding patient biology. We are building the world’s leading predictive simulation of patient biology. We will empower the biopharma industry by informing the right experiments that identify and validate disease driving hidden effects. Drug Discovery, Biotechnology, Artificial Intelligence, in silico, Cell Biology, Simulated Experiments, Bioinformatics, and Pharmaceuticals Type: | 4 | 0 | 4 | 102 |
 | Crescendo Biologics Limited Crescendo Biologics - The T cell Enhancing Company Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical … Type: | 4 | 2 | 3 | 56 |
 | EryPharm EryPharm is a biotech start-up company dedicated to the development and the operation of a large-scale process for the production of Red Blood Cells from stem cells. The technology has been developed by Dr. Luc Douay and his team at the Paris Sorbonne university. You can contact EryPharm through our website: http://erypharm.com/contact.html Or you can contact Loïc Tron directly: www.linkedin.com/in/loictron Type: | 9 | 1 | 8 | 4 |
 | Quantum Surgical Standardize minimally invasive cancer treatment Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA … Tags: FrenchTech2030 Type: | 38 | 10 | 33 | 119 |
 | Inotrem Control innate immunity Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases. Type: | 7 | 6 | 1 | 33 |
 | Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule … Type: | 9 | 5 | 5 | 82 |
 | Mintz Built on excellence. Driven by change. Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. is a general practice, full-service Am Law 100 law firm employing approximately 600+ attorneys serving clients worldwide. We are headquartered at One Financial Center in Boston’s Financial District and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, Washington, DC, and an office in Toronto, Canada. Mintz was founded in 1933 by Haskell Cohn and Benjamin Levin. The firm’s Managing Member is Robert I. Bodian. Our collaborative attorneys work within four core practice areas — Transactional, Intellectual Property, Litigation & … Type: | 8 | 2 | 3 | 1,353 |
 | TechCrunch Technology news and analysis with a focus on founders and startup teams TechCrunch, founded on June 11, 2005, is a news website dedicated to the tech scene. We provide breaking technology news, opinions, and analysis on tech companies from around the world. From publicly traded tech companies to emerging startups and venture capital funding rounds, TechCrunch is your number one guide for all things startups. blogging, startups, tech, technology, VC, venture capital, entrepreneurs, founders, and investors Type: | 335 | 216 | 51 | 380 |
 | Calliditas Therapeutics Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the lives of patients. Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products. Type: | 5 | 2 | 0 | 238 |
 | Milano Finanza [Automatic translation follows] The best of economic and financial information, always at your disposal. MF-Milano Finanza is the national financial and economic newspaper, with the primacy of information on the stock market, economy, investments and markets. A direct line to Piazza Affari and the main world stock exchanges. With dedicated sections: Online trading, Technical Analysis, ETF, Covered Warrant, Private Equity, Shipping & Logistics and on Saturday with Milano Finanza important insights into the world of managed savings, securities and real estate investments. The correctness, truthfulness and authoritativeness of the newspaper are recognized by the target and by professionals both at … Type: | 5 | 5 | 0 | 334 |
 | Talas Partners [Automatic translation follows] The right financing at the right time! Talas Partners is your partner of excellence to propel your company's innovation towards new horizons. Who are we? Much more than a simple consulting firm in innovation financing, we become your partner to achieve your entrepreneurial goals and lead you to success. Our passion is to transform each innovative project into a successful entrepreneurial success. Our Mission We have a clear mission: to help Startups and SMEs develop their business by mobilizing public or private financing. Our Support Present in the innovation ecosystem for a very long time, we guide … Type: | 4 | 1 | 3 | 3 |
 | CorWave CorWave develops and manufactures innovative implantable blood pumps based on a breakthrough membrane technology. CorWave is a French company developing innovative cardiac assist devices. CorWave’s wave membrane pump is a breakthrough technology that differs from today’s commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave’s membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up … Tags: FrenchTech120 Type: | 25 | 11 | 22 | 96 |
 | Bon Vivant Animal-free dairy proteins, for a sustainable future. We are a French biotechnology company developing cutting-edge precision fermentation techniques, dedicated to take part in the environmental transition within the dairy production sector. Our innovative technology enables the production of dairy proteins without the need for animals, significantly reducing the ecological footprint. By providing our clients with cutting-edge, sustainable ingredients, we empower them to create a diverse range of dairy products identical to those you already love, both environmentally conscious and nutritionally rich. Join us on our journey to shaping a future where ethical dairy alternatives are complementary to conventional farming and … Type: | 45 | 12 | 34 | 111 |
 | Predict4Health AI-powered Precision Medicine for Organ Failure Our mission is to improve patients’ live and healthcare systems by postponing organ failure with the power of AI. 💪 Our products : 📊 A Decision making tool based on iBox : Predigraft helps physicians monitor transplanted patients by providing allograft survival prognosis. 📱 A Smart telemonitoring of chronic patients : Apilife is a fully connected platform acting as a medical hub for patients and their medical teams. 🧬 A Digital Biomarker for clinical trials : Our technology can be used to design clinical trials and to assess kidney allograft survival. Medicine, Machine Learning, … Type: | 41 | 6 | 31 | 26 |
 | BRAIN Biotech AG Developing a biobased future is our passion. Industrial biotechnology is our business. BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator. The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in … Type: | 3 | 1 | 1 | 190 |
 | Phytolon Natural Food Colors Phytolon offers natural food colors, uniquely positioned to comply with the consumers needs for healthy food, and with the industry requirements for cost-efficiency and high quality. Phytolon leverages a novel and sustainable fermentation-based technology by which betalain natural colors are produced in baker's yeast. food colors, natural ingredients, yeast, fermentation, sustainability, biotechnology, and foodtech Type: | 2 | 0 | 2 | 26 |
 | Regeneration.VC Supercharging Consumer-Powered Climate Innovation Regeneration.VC is a global venture capital firm investing in Consumer ClimateTech innovation. Our investment strategy targets early-stage companies demonstrating asymmetric return potential by insetting environmentally aligned solutions within consumer value chains. Our mission is to realize abundance within planetary boundaries through regenerative consumer value chains. Have an innovation ready to supercharge? Submit here: https://form.fillout.com/t/dDYPidgNx4us Circular Economy, Sustainable Investing, Venture Capital, Consumer, Climate Tech, Regeneration, and Consumer ClimateTech Type: | 51 | 0 | 51 | 19 |
 | Sixth Street Global investors developing themes and offering solutions to companies across all stages of growth Sixth Street is a global investment firm with over $75 billion in assets under management and committed capital. We use our long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street is dedicated to cross-platform collaboration at scale. We have more than 600 team members including over 250 investment professionals operating across our global locations. We invest through our diversified, collaborative investment platforms: TAO, Growth, Direct Lending, Strategic Capital, Fundamental Strategies, Infrastructure, … Type: | 5 | 3 | 2 | 732 |
 | BeBeez Italia [Automatic translation follows] The first publisher specialized in news and services on private investments in venture capital and debt EdiBeez is the publisher of BeBeez.it and CrowdfundingBuzz.it BeBeez is an online newspaper registered with the Court of Milan (Authorization no. 102 of April 3, 2013), born in the spring of 2013 from an idea by Stefania Peveraro (head of service of MF Milano Finanza) and Anna Gervasoni (general director of the Italian Association of Private Equity and Venture Capital, AIFI). Crowdfunding Buzz is a magazine dedicated to collecting news and information related to all forms of crowdfunding. Born in December … | 41 | 0 | 41 | 10 |
 | Osage University Partners (OUP) Venture capital for university innovation. All sectors, all stages, all in. Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups that are commercializing university research. OUP firmly believes that universities provide an unparalleled innovation engine and we have partnered with over 100 of the most entrepreneurial universities and research centers to invest in their startups. Profits are shared with affiliated institutions to further promote the university entrepreneurial ecosystem. Physical Sciences, Life Science, entrepreneurship, University Innovation, VC, Venture Capital, investing, startups, university startup, technology transfer, biotech, and science Type: | 5 | 1 | 4 | 21 |
 | LCA Studio Legale Your business partner LCA is an independent, full-service law firm, specialised in providing legal assistance to companies worldwide. Our offices are in Italy (Milan, Rome, Genoa, Treviso), Belgium (Brussels), and the United Arab Emirates (Dubai), where we operate in an International Partnership with IAA Middle East Legal Consultants LLP. LCA employs over 250 professionals specialised in all main areas of commercial, corporate, banking, finance, restructuring, tax, criminal, real estate, and labour law, and in all aspects of business law - including intellectual property, new technologies, transportation and insurance issues, art and food regulations - and in the protection of family … | 9 | 2 | 6 | 383 |
 | ISALT [Automatic translation follows] Financing the new French industry and meeting the challenge of transitions "Our goal is to grow French companies through long-term investment" ISALT is a portfolio management company whose mission is to invest in the long term in the capital of listed or unlisted French companies. Since its creation in 2020, ISALT has set itself the ambition of developing a long-term investment platform with the aim of providing stable and constructive capital to French companies operating in key sectors for our economy. As such, it implements an investment strategy that consists of taking significant and long-term stakes in … Type: | 7 | 5 | 2 | 21 |
 | The Drawdown Connecting an exclusive community of operational leaders in the private capital fund industry. As the private capital fund industry moves into a new phase of maturity and institutionalisation, the pressure and complexity faced by operational professionals is increasing exponentially. ‘The Drawdown’ offers exclusive access to an expert and supportive network where connections, valuable insight and best practice are shared, including The Drawdown Awards, Summer and Winter Operational Leaders’ Summits as well as focused invitation only events. We are empowering our members to succeed in this complex environment and to play an instrumental role in shaping the future of our industry. … Type: | 8 | 2 | 7 | 4 |
 | Pi-Cardia Leading the way for leaflet modification Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCutTM is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access. Medical Device, Aortic Stenosis, Precautions Catheter-System, Cardiovascular, leaflet … Type: | 1 | 1 | 0 | 59 |
 | PEAK LIFECYCLES HR - Europe & the US Beyond the people you want, get the people you need PEAK LIFECYCLES HR is an international Executive Search and Talent Management company dedicated to Global "Care environment" markets and their stakeholders. Placing the analysis of the business life cycle, and that of products, skills, and projects at the heart of its activity, Peak Lifecycles' unique, innovative expertise is founded on its anticipation of market requirements. OUR OFFERS: Executive Search, Talent Management, Organizational audit, Executive Coaching We also developed an offer dedicated to Startups and their lifecycles. Executive Search, Talent Management, Life Sciences, Market Access, Medical, Business Operation, Digital , Food, … Type: | 20 | 0 | 19 | 12 |
 | GIMLI Leverage Real World Evidence in oncology Gimli empowers medical professionals to structure medical data. We extract and structure data directly from the EMR to streamline RWD, allowing the generation of strong RWE. Ask us for a demo! Gimli is a Startup working with university hospitals, pharmaceutical companies, data analytics providers, and startups. Type: | 29 | 2 | 11 | 6 |
 | Bicycle Therapeutics Precision-Guided Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC … Type: | 6 | 2 | 1 | 276 |
 |  Mablink Bioscience Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D Type: | 15 | 9 | 10 | 35 |
 | GLEAMER Medical-Grade AI for Radiology GLEAMER offers a suite of AI solutions for radiology that encapsulate medical-grade expertise. Our company wants to support imaging readers to secure diagnoses for all patients at all times while improving comfort and workflow efficiency. Our team imagines and develops solutions booth at the level of an expert and is easy to integrate thanks to the joint work of a multi-disciplinary team encapsulating AI and radiologist experts. GLEAMER has already been integrated into more than 650 institutions in each part of the world. 🏅Alexander Margulis award - Scientific excellence for the BoneView clinical study 🏅 🏅 … Type: | 22 | 10 | 14 | 78 |
 | PE Cube You're Good, get Better. PE Cube is a SaaS solution for each team member of Private Equity management companies to optimize fund management’s performance and Investor Relation while enabling a rich, reliable and transparent communication towards each of its stakeholders. PE Cube is based on 20 years of Private Equity practice and on the key-belief that data is crucial to each level of fund management. This is why PECube is designed to ensure flawless end-to-end processing to express the full potential for monitoring and steering fund management activity. Each general partner member is thus equipped to ensure reliability, security and … Type: | 42 | 4 | 42 | 15 |
 | Mosaic TX An oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients. ABOUT US Mosaic Therapeutics is an oncology therapeutics company using advanced computational methods and next-generation cancer models to discover and develop novel targeted therapies. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active programmes across a variety … Type: | 2 | 1 | 1 | 27 |
 | AMSilk GmbH | Biotech Materials 🌐 The first industrial supplier of advanced biomaterials made from spider silk-based proteins 🎯 Enabling true change AMSilk is a frontrunner in advanced biomaterials made from spider silk-based proteins. Using a patented technology platform, protected by a best-in-class patent portfolio, we are pushing boundaries in the field of bio-based materials. At AMSilk, we turn man-made proteins into formulations, including fibers and yarns, hydrogels and silk powder. The high-performance qualities of our material enable a wide range of applications in the textile, homecare, biomedical, and automobile industries and bring breakthrough benefits for products and customers. biotech, biotech materials, biopolymers , zero-waste … Type: | 3 | 1 | 2 | 76 |
 | Virtonomy.io Accelerate and de-risk medical device development with digital patient twins and simulation Virtonomy introduces v-Patients, enabling medical device developers to perform development and testing in a virtual environment, thereby accelerating development, reducing risks, expenses, and regulatory burden. Our end-to-end digital twin and simulation solution is based on an ever-expanding database of real clinical data to reflect anatomical variability, demographic diversity and pathological conditions. digital health, virtual patients, digital twins, clinical trials, simulation, machine learning, AI, SaaS, simulated trials, cardiac database, and medtech Type: | 4 | 0 | 4 | 25 |
SMB